Evoq Remedies Ltd

Evoq Remedies Other Announcement

Evoq Remedies Ltd received approval from the Registrar of Companies to extend the deadline for its 16th Annual General Meeting until 30th October 2026.

Evoq Remedies Insolvency Petition

NCLT admitted CIRP against Evoq Remedies Ltd for a Rs.1.95 Crore operational debt. An IRP has been appointed, and a moratorium is in effect.

Value

₹1.95 Cr

Evoq Remedies Insolvency Petition

An operational creditor has filed an insolvency petition against Evoq Remedies under IBC Section 9. The NCLT admission initiates the CIRP process, posing significant risk for shareholders.

Evoq Remedies Financial Results

Evoq Remedies Limited reported audited financial results for the year ended March 31, 2026. The auditor issued a qualified opinion citing material uncertainty regarding going concern.

Evoq Remedies H2 FY26 Results: Net Loss of ₹0.3 Cr

Evoq Remedies Ltd reported a net loss of ₹0.3 Cr for H2 FY26.

Key figure

Net loss ₹0.3 Cr

Evoq Remedies Financial Results

Evoq Remedies Limited reported annual revenue of ₹26.76 Crore for FY2026. The board also appointed M/s. Jay Pandya & Associates as secretarial auditors for FY2025-26.

Value

₹26.76 Cr

Evoq Remedies Board Meeting Date

Evoq Remedies rescheduled its board meeting from May 27 to May 30, 2026. Directors will consider audited financial results for the fiscal year ended March 31.